| Literature DB >> 27184509 |
Ovgu Cinpolat1, Zeynep Nil Unal2, Onur Ismi3, Aysegul Gorur4, Murat Unal5.
Abstract
INTRODUCTION: Salivary gland tumors (SGTs) are rare head and neck malignancies consisting of a spectrum of tumors with different biological behaviors.Entities:
Keywords: MicroRNA; Pathogenesis; Patogenia; Salivary gland tumor; Tumor de glândula salivar; miR-21; miR-30e
Mesh:
Substances:
Year: 2016 PMID: 27184509 PMCID: PMC9444796 DOI: 10.1016/j.bjorl.2016.03.013
Source DB: PubMed Journal: Braz J Otorhinolaryngol ISSN: 1808-8686
Histopathologic types of tumors in the patient group.
| Tumor type | Percentage |
|---|---|
| Warthin's tumor | 9/20 (45%) |
| Pleomorphic adenoma | 7/20 (35%) |
| Squamous cell carcinoma | 2/20 (10%) |
| High grade mucoepidermoid carcinoma | 1/20 (5%) |
| Adenocarcinoma | 1/20 (5%) |
Figure 1Comparison of plasma microRNA expression profiles between benign tumor group and control group.
MicroRNAs showing statistically significant fold changes by comparing the plasma samples of benign tumor and control groups with p values were presented.
| MicroRNA type | Fold regulation | |
|---|---|---|
| Mir-21 | −2.5197 | 0.04 |
| Mir-23a | −13.05 | 0.00005 |
| Mir-27a | −21.4 | 0.00005 |
| Mir-125b | −4.644 | 0.031 |
| Mir-126 | −9.2 | 0.00008 |
| Mir-30e | −64.38 | 0.0007 |
| Mir-146a | −3.5 | 0.044 |
| Mir-223 | −10.34 | 0.0022 |
Figure 2Comparison of tissue microRNA expression profiles between benign and malignant tumor groups.
MicroRNA expression of malignant tumor group compared to benign tumor group in tissue samples showing statistically significant fold changes were shown.
| MicroRNA type | Fold regulation | |
|---|---|---|
| Mir-21 | +5.23 | 0.0006 |
| Mir-31 | +2.24 | 0.02 |
| Mir-199a | +2.36 | 0.013 |
| Mir-146b | +3.21 | 0.013 |
| Mir-345 | +18.063 | 0.041 |
Figure 3Heat map diagram of patients’ microRNA expression profiles in tissue samples was presented. P (patient) 8, 9, 18, 20 were malignant salivary gland tumor patients, others were benign ones.
Figure 4Comparison of plasma samples of benign and malignant tumor group for microRNA expression profiles.
Previously published studies concerning the relationship between MicroRNAs and salivary gland tumors.
| Author | Published year | Tumor type | Study design | Result |
|---|---|---|---|---|
| Zhang et al. | 2009 | Pleomorphic adenoma | Pleomorphic adenoma tissue samples were compared with normal salivary gland tissue | Several microRNAs had dysregulations in tumor group. |
| Liu et al. | 2012 | ACC | ACC tissue samples were compared with pleomorphic adenoma and normal tissues by using cell culture. | miR-155 is up regulated in ACC cells and causes proliferation, tumor growth and increases invasion |
| Mitani et al. | 2013 | ACC | Tumor tissue samples were compared with normal salivary gland tissue | miR-17-92 cluster expression is related to poor outcome |
| He et al. | 2013 | ACC | Cell culture of metastatic cell lines were inoculated to mice | miR-181a suppresses metastasis in ACC |
| Chen et al. | 2014 | ACC | Cell cultures were obtained from metastatic and non-metastatic cell lines of ACC | 17 microRNAs had dysregulation in metastatic cell lines. |
| Veit et al. | 2015 | ACC | ACC tissue samples were compared with SCC tissues. | miR-214, 125a, 574, 199a/b-3p, 199a-5p were up-regulated in ACC. |
| Kiss et al. | 2015 | ACC | ACC tissue samples were compared with normal salivary gland tissue | 7 microRNAs were upregulated and 9 were downregulated. |
| Kiss et al. | 2015 | ACC | ACC tissue samples were compared with normal salivary gland tissue | miR-let-7b and miR-193b were down regulated in tissue samples |
| Cinpolat et al. | Benign and malignant SGTs | (1) Comparison of saliva and serum samples between benign tumors, malign tumors and control group. | Dysregulation in expression of different types of microRNAs occur according to biological behavior of the SGT. Mir-21and 30e are down-regulated in benign SGT group, up-regulated in malignant ones. |
ACC, adenoid cystic carcinoma; SGT, salivary gland tumors; miR, microRNA.
Presented study.